Opus Genetics (IRD) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Opus Genetics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $324K and 7 sold $19.3M of IRD stock on the open market.
Get emailed when insiders cluster-buy stocks like IRD
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
IRD insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $3.0M | 6 |
| Q2 2026 | — | 0 | $7.6M | 7 |
| Q1 2026 | — | 0 | $181K | 4 |
| Q4 2025 | $324K | 2 | $8.6M | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Opus Genetics, Inc. insider reported open-market purchases totaling $324K, while 7 insiders reported sales totaling $19.3M. 1 of 18 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Foundation Fighting Blindness Retinal Degeneration FundSee Remarks | Sell | 556,0003,236,171 held (−15%) | $4.96 | $2.8M | -6.2% | — |
| Sep 8SEC | Robert E. GagnonCFO | Sell Plan | 28,000556,375 held (−5%) | $4.54 | $127K | +2.4% | — |
| Jul 27SEC | George MagrathCEO | Sell | 9,4751,731,869 held (−1%) | $2.95 | $28K | +57.6% | — |
| Jul 27SEC | Robert E. GagnonCFO | Sell | 7,783584,375 held (−1%) | $2.95 | $23K | +57.6% | — |
| Jul 27SEC | Benjamin R YerxaPresident | Sell | 7,429704,106 held (−1%) | $2.97 | $22K | +56.6% | — |
| Jul 27SEC | Joseph K SchachleCOO | Sell | 4,644291,440 held (−2%) | $2.94 | $14K | +58.2% | — |
| May 20SEC | Foundation Fighting Blindness Retinal Degeneration FundSee Remarks | Sell | 1,700,0003,792,171 held (−31%) | $4.35 | $7.4M | +6.9% | — |
| Apr 27SEC | George MagrathCEO | Sell | 9,5111,741,344 held (−1%) | $5.22 | $50K | -10.9% | — |
| Apr 27SEC | Robert E. GagnonCFO | Sell | 7,842592,158 held (−1%) | $5.18 | $41K | -10.2% | — |
| Apr 27SEC | Ashwath JayagopalChief Scientific & Dev. Ofc. | Sell | 7,542509,233 held (−1%) | $5.19 | $39K | -10.4% | — |
| Apr 27SEC | Benjamin R YerxaPresident | Sell | 7,470711,535 held (−1%) | $5.24 | $39K | -11.3% | — |
| Apr 27SEC | Joseph K SchachleCOO | Sell | 4,697296,084 held (−2%) | $5.22 | $25K | -10.9% | — |
| Apr 27SEC | Rabourn Amy ZarembaHead Of Fin. Quality Assurance | Sell | 1,641188,671 held (−1%) | $5.20 | $9K | -10.6% | — |
| Mar 18SEC | George MagrathCEO | Sell | 24,4381,750,855 held (−1%) | $5.21 | $127K | -10.7% | — |
| Mar 18SEC | Joseph K SchachleCOO | Sell | 3,719300,781 held (−1%) | $5.25 | $20K | -11.4% | — |
| Mar 18SEC | Ashwath JayagopalChief Scientific & Dev. Ofc. | Sell | 3,719516,775 held (−1%) | $5.12 | $19K | -9.2% | — |
| Mar 18SEC | Rabourn Amy ZarembaHead Of Fin. Quality Assurance | Sell | 2,816190,312 held (−1%) | $5.25 | $15K | -11.4% | — |
| Dec 31SEC | Cam GallagherDirector | Buy | 83,000new position | $1.97 | $164K | +136.0% | — |
| Dec 31SEC | Cam GallagherDirector | Buy | 81,0001,891,430 held (+4%) | $1.98 | $160K | +134.8% | — |
| Dec 11SEC | Foundation Fighting Blindness Retinal Degeneration FundSee Remarks | Sell | 4,000,0005,492,171 held (−42%) | $2.15 | $8.6M | +116.3% | — |
Insiders at Opus Genetics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration FundSee Remarks | — | $18.8M | Oct 2, 2026 | — |
| Cam GallagherDirector | $324K | — | Dec 31, 2025 | — |
| George MagrathCEO | — | $205K | Jul 27, 2026 | — |
| Robert E. GagnonCFO | — | $191K | Sep 8, 2026 | — |
| Benjamin R YerxaPresident | — | $61K | Jul 27, 2026 | — |
| Ashwath JayagopalChief Scientific & Dev. Ofc. | — | $58K | Apr 27, 2026 | — |
| Joseph K SchachleCOO | — | $58K | Jul 27, 2026 | — |
| Rabourn Amy ZarembaHead Of Fin. Quality Assurance | — | $23K | Apr 27, 2026 | — |
IRD stock: common questions
Are Opus Genetics, Inc. insiders buying IRD stock?
In the past 12 months, 1 insiders reported open-market purchases of IRD worth $324K. The latest was Director Cam Gallagher bought $164K of IRD at $1.97 — opens a new position.
Are Opus Genetics, Inc. insiders selling IRD stock?
7 insiders reported sales worth $19.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IRD's 52-week range?
Over the past year IRD has traded between $1.74 and $6.07. It last closed at $4.65 on Oct 9, 2026.